Performance-enhancing drugs snare nonathletes, too

Journal of Family Practice

Volumn 58, Issue 1, 2009, Pages 16-23

  Fernandez, Marifel Mitzi F ^a,b   Hosey, Robert G ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANDROGEN; ANDROMAX; ANDROSTAT 100; ANDROSTENEDIONE; ASPARTATE AMINOTRANSFERASE; CAFFEINE; CELL TECH HARDCORE; CREATINE; EPHEDRINE; ERYTHROPOIETIN; ESTRADIOL; FEMME ADVANTAGE; GESTAGEN; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN; HUMAN GROWTH HORMONE; HYDROCORTISONE; ILLICIT DRUG; LOW DENSITY LIPOPROTEIN; METANDIENONE; MUSCLE MARKETING; NANDROLONE DECANOATE; NORADRENALIN; NOZ; OXYMETHOLONE; PARABOLIN; PRASTERONE; RECOMBINANT ERYTHROPOIETIN; REJUVINIX; SILDENAFIL; SOMATOMEDIN; STANOZOLOL; TESTOSTERONE; TESTOSTERONE DERIVATIVE; TETRAHYDROGESTRINONE; UNCLASSIFIED DRUG;

ACNE; ACROMEGALY; AGGRESSION; ALOPECIA; ANXIETY; ATHLETE; CANCER RISK; CARDIOMEGALY; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DYSPEPSIA; EARLY MENOPAUSE; ENDOMETRIUM CANCER; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FEMINIZATION; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; INJECTION SITE PAIN; INSULIN RESISTANCE; LIVER TOXICITY; LUNG EMBOLISM; MENSTRUAL IRREGULARITY; MENTAL DISEASE; MUSCLE CRAMP; MYOPATHY; PANIC; PRIAPISM; REVIEW; SEXUAL DYSFUNCTION; SHORT STATURE; SIDE EFFECT; STROKE; SUDDEN DEATH; TACHYCARDIA; TESTIS ATROPHY; VIRILIZATION; VISUAL DISORDER; WEIGHT GAIN;

DIETARY SUPPLEMENTS; DOPING IN SPORTS; HUMANS; MALE; PHYSICAL FITNESS; SUBSTANCE-RELATED DISORDERS; TESTOSTERONE CONGENERS; YOUNG ADULT;

EID: 58549104717     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. De Rose E. Doping in athletes - an update. Clin Sports Med. 2008;27:107-130.
2. Di Luigi L. Supplements and the endocrine system in athletes. Clin Sports Med. 2008;27:131-151.
3. Parkinson A, Evans N. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006; 38:644-651.
4. National Institute on Drug Abuse. Monitoring the future. National results on adolescent drug use. Overview of key findings. National Institutes of Health. 2007. Available at: http://monitoringthefuture.org/pubs/ monographs/overview2007.pdf. Accessed November 22, 2008.
5. Centers for Disease Control and Prevention. Youth risk behavior surveillance-United States, 2007. MMWR. 2008;57 (SS-4). Available at http://www.cdc.gov/HealthyYouth/yrbs/pdf/yrbss07-mmwr.pdf. Accessed November 22, 2008.
6. Hoffman J, Faigenbaum A, Ratamess NA, et al. Nutritional supplementation and anabolic steroid use in adolescents. Med Sci Sports Exerc. 2008;40:15-24.
7. Faigenbaum A, Zaichkowsky L, Gardner DE, et al. Anabolic steroid use by male and female middle school students. Pediatrics. 1998;101:E6.
8. Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics. 2006;117:e577-589.
9. Tokish J, Kocher M, Hawkins R. Ergogenic aids: a review of basic science, performance, side effects, and status in sports. Am J Sports Med. 2004;32:1543-1553.
10. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335:1-7.
11. McDevitt E. Ergogenic drugs in sports. DeLee & Drez's Orthopaedic Sports Medicine. Philadelphia: Elsevier Science; 2003:471-483.
12. Kibble M, Ross M. Adverse effects of anabolic steroids in athletes. Clin Pharmpoe. 1987;6:686-692.
13. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a review for the clinician. Sports Med. 2002;32:285-296.
14. Blue JG, Lombardo JA. Steroids and steroid-like compounds. Clin Sports Med. 1999;18:667-689.
15. Rockhold R. Cardiovascular toxicity of anabolic steroids. Ann Rev Pharmacol Toxicol. 1993;33:497-520.
16. Parssinen M, Kujale U, Vartainen E, et al. Increased premature mortality of competitive power lifters suspected to have used anabolic agents. Int J Sports Med. 2000;21:225-227.
17. Nieminen MS, Ramo MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J. 1996;17:1576-1583.
18. Parssinen M, Seppala T. Steroid use and long-term health risks in former athletes. Sports Med. 2002;32:83-94.
19. Dhar R, Stout W, Link MS, et al. Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc. 2005;80:1307-1315.
20. Melchert RB, Welder AA. Cardiovascular effects of androgenic anabolic steroids. Med Sci Sports Exerc. 1995;27:1252-1262.
21. Sullivan M, Martinez C, Gennis P, et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41:1-15.
22. Malvey T, Armsey T. Tetrahydrogestrinone: the discovery of a designer steroid. Curr Sports Med Rep. 2005;4:227-230.
23. Noakes TD. Tainted glory - doping and athletic performance. N Engl J Med. 2004;351:847-849.
24. Fourcroy J. Designer steroids: past, present and future. Curr Opin Endocrinol Diabetes Obes. 2006;13:306-309.
25. Death A, McGrath K, Kazlauskas R, et al. Tetrahydrogestrinone is a potent androgen and progestin. J Clin Endocrinol Metabol. 2004;89:2498-2500.
26. Center for Food Safety and Applied Nutrition. Food and Drug Administration. Questions and Answers. Androstenedione. March 11, 2004. Available at: http://www.cfsan.fda.gov/~dms/androqa.html. Accessed November 22, 2008.
27. King DS, Sharp RL, Vukovich MD, et al. Effect of oral andrastenedione on serum testosterone & adaptations to resistance training in young men. A randomized control trial. JAMA. 1999;281:2020-2028.
28. Breeder C, Quindry J, Brittingham K, et al. The Andre project. Physiological & hormonal influences of andrastenedione supplement in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med. 2000;160:3093-3104.
29. Leder B, Longcope C, Catlin DH, et al. Oral andrastenedione administration and serum testosterone concentrations in young men. JAMA. 2000;283:779-782.
30. Yesalis C, Bahrke M. Anabolic-androgenic steroids and related substances. Curr Sports Med Rep. 2002;1:246-252.
31. Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab. 1998;83:1928-1934.
32. Boyce EG. Use and effectiveness of performance-enhancing substances. J Pharm Pract. 2003;16:22-36.
33. Meyers DE, Cuneo RC. Controversies regarding the effects of growth hormone on the heart. Mayo Clin Proc. 2003;78:1521-1526.
34. Dean H. Does exogenous growth hormone improve performance? Clin J Sports Med. 2002;12:250-253.
35. McDuff DR, Baron D. Substance use in athletics: a sports psychiatry perspective. Clin Sports Med. 2005;24:885-897.
36. Keisler BD, Hosey RG. Ergogenic aids: an update on ephedra. Curr Sports Med Rep. 2005;4:231-235.
37. Sinclair CJ, Geiger JD. Caffeine use in sports. A pharmacologic review. J Sports Med Phys Fitness. 2000;40:71-79.
38. US Food and Drug Administration. Questions and answers about FDA's actions on dietary supplements containing ephedrine alkaloids. February 6, 2004. Available at: http://www.fda.gov/oc/initiatives/ephedra/february2004/qa-020604. html. Accessed November 23, 2008.
39. Motl R, O'Connor P, Tubandi L, et al. Effect of caffeine on leg muscle pain during cycling exercise among females. Med Sci Sports Exerc. 2006;38:598-604.
40. Del Coso J, Estevez E, Mora-Rodriguez R. Caffeine effects on short-term performance during prolonged exercise in the heat. Med Sci Sports Exerc. 2008;40:744-751.
41. Schneiker KN, Bishop D, Dawson B, et al. Effects of caffeine on prolonged intermittent-sprint ability in team sport athletes. Med Sci Sports Exerc. 2006;38:578-585.
42. Keisler BD, Armsey TD. Caffeine as an ergogenic aid. Curr Sports Med Rep. 2006;5:215-219.
43. Rogers N, Dinges D. Caffeine: implications for alertness in athletes. Clin Sport Med. 2005;24:e1-e13.
44. Kraemer W, Volek J. Creatine supplementation, its role in human performance. Clin Sports Med. 1999;18:651-666.
45. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci. 1992;83:367-374.
46. Demant TW, Rhodes EC. Effects of creatine supplementation on exercise performance. Sports Med. 1999;28:49-60.
47. Balsom PD, Harridge S, Soderlund K, et al. Creatine supplementation per se does not enhance endurance exercise performance. Acta Physiol Scand. 1993;149:521-523.
48. Metzl J, Small E, Levine SR, et al. Creatine use among young athletes. Pediatrics. 2001;108:421-425.
49. Longman J. New suspect in sports doping is, no joke, Viagra. The New York Times. November 23, 2008. Available at: http://www.nytimes.com/2008/11/ 23/sports/23viagra.html?scp=2&sq=Viagra&st=cse. Accessed November 23, 2008
50. Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mt. Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med. 2004;141:169-177.
51. Hsu AR, Barnholt KE, Grundman NK, et al. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J Appl Physiol. 2006;100:2031.
52. Kurtzweil P. An FDA guide to dietary supplements. FDA Consumer. Sept-Oct, 1998. Available at: http://www.fda.gov/fdac/features/1998/598-guid. html. Accessed November 23, 2008.
53. Geyer H, Parr M, Mareck U, et al. Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids - results of an international study. Int J Sports Med. 2004;25:124-129.